Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Benadryl
|
| gptkbp:approves |
1951
|
| gptkbp:brand |
Phenergan
|
| gptkbp:contraindication |
gptkb:sneaker
respiratory depression severe liver disease pediatric patients under 2 years |
| gptkbp:discovered_by |
Rudolf F. Schmid
|
| gptkbp:formulation |
gptkb:product
gptkb:tablet injection suppository |
| https://www.w3.org/2000/01/rdf-schema#label |
promethazine
|
| gptkbp:ingredients |
C17 H20 N2 S
|
| gptkbp:interacts_with |
gptkb:beer
CNS depressants MAO inhibitors anticholinergic drugs |
| gptkbp:is_atype_of |
R06 A D02
|
| gptkbp:is_used_for |
nausea
vomiting sedation motion sickness allergy symptoms |
| gptkbp:legal_issue |
prescription-only
|
| gptkbp:lifespan |
10 to 19 hours
|
| gptkbp:manager |
oral
intravenous intramuscular |
| gptkbp:metabolism |
liver
|
| gptkbp:pharmacokinetics |
dopamine receptor antagonist
H1 receptor antagonist oral bioavailability 25% to 50% |
| gptkbp:related_to |
gptkb:drug
phenothiazine |
| gptkbp:side_effect |
dizziness
confusion seizures urticaria drowsiness dry mouth blurred vision anaphylaxis hypotension extrapyramidal symptoms neuroleptic malignant syndrome |
| gptkbp:storage |
room temperature
dry place away from light |
| gptkbp:type_of |
58-33-3
|